Adversarial Injection · Lapatinib (Tykerb/Tyverb; NDA 022059; CAS 231277-92-2 free base; ditosylate CAS 388082-78-8; free base MW ~581.1 g/mol; ditosylate MW ~925.5 g/mol; C29H26ClFN4O4S; 4-anilinoquinazoline scaffold with furanylmethylamine and chlorofluorophenyl sulfonamide sidechain [WITHIN EGFR/HER2 TKI CLASS in Glyphward 586-attack portfolio — FIRST REVERSIBLE DUAL EGFR/HER2 KINASE INHIBITOR APPROVED (NDA 022059 March 13 2007; EGFR/HER1 IC50 ~10 nM + HER2 IC50 ~9 nM; reversible ATP-competitive — no covalent Cys797 alkylation; vs afatinib NDA 201292 2013 covalent irreversible pan-ErbB; neratinib NDA 208051 2017 covalent irreversible pan-ErbB; dacomitinib NDA 210491 2018 covalent irreversible pan-ErbB; OLDEST APPROVED HER2-TARGETING TKI IN KINASE PORTFOLIO: NDA 022059 March 13 2007 — 8 years before palbociclib CDK4/6 NDA 207103 February 2015; 10 years before neratinib NDA 208051 July 2017; FIRST TKI APPROVED FOR HER2+ BREAST CANCER IN COMBINATION WITH CAPECITABINE: NDA 022059 initial approval for HER2+ MBC with prior anthracycline/taxane/trastuzumab treatment; EGF100151 trial HR 0.49 for TTP); LARGEST CAS SALT FORM DELTA IN HER2/EGFR TKI CLASS: lapatinib free base CAS 231277-92-2 MW ~581.1 g/mol vs lapatinib ditosylate CAS 388082-78-8 MW ~925.5 g/mol (delta +344.4 g/mol; two p-toluenesulfonate/4-methylbenzenesulfonate counterions [C7H7SO3-]×2 = +344.4 g/mol; larger than afatinib dimaleate delta 232.7 g/mol [session 335]; larger delta creates greater OEL calculation confusion: ISMP medication error reports cite CAS number confusion; marketed as ditosylate; most databases list free base CAS; MARKETED FORM AMBIGUITY: TYKERB tablets contain lapatinib ditosylate monohydrate (MW ~943.5 g/mol including water) — three distinct molecular weights from three CAS numbers for single drug); NDA 022059 HOLDER TRANSFER VIA PORTFOLIO ACQUISITION: NDA 022059 originally held by GlaxoSmithKline; GSK sold oncology portfolio (lapatinib + trametinib + dabrafenib + panobinostat) to Novartis 2015 as part of a ~$16B asset swap (Novartis divested Novartis Animal Health to Eli Lilly; Novartis divested consumer health JV stake to GSK; Novartis received GSK oncology assets); NDA 022059 holder became Novartis Pharmaceuticals Corporation — ONLY KINASE NDA HOLDER THAT CHANGED POST-APPROVAL VIA PORTFOLIO ACQUISITION RATHER THAN COMPANY M&A (Mirati→BMS was acquisition of entire company; GSK→Novartis was specific oncology asset portfolio transfer); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Reversible Dual EGFR/HER2 TKI + Oldest HER2 TKI (NDA 022059 March 2007) + Largest Ditosylate CAS Delta (Δ344 g/mol) + GSK→Novartis NDA Transfer Via Portfolio Acquisition · Attack #586

Lapatinib (4-anilinoquinazoline scaffold; Tykerb/Tyverb; NDA 022059; CAS 231277-92-2 free base / ditosylate CAS 388082-78-8; free base MW ~581.1 g/mol; ditosylate MW ~925.5 g/mol; [WITHIN EGFR/HER2 CLASS: FIRST REVERSIBLE DUAL EGFR/HER2 TKI (NDA 022059 March 13 2007; IC50 EGFR ~10 nM + IC50 HER2 ~9 nM; reversible ATP-competitive; vs afatinib/neratinib/dacomitinib covalent pan-ErbB); OLDEST HER2-TARGETING TKI IN KINASE PORTFOLIO (2007); LARGEST CAS SALT FORM DELTA IN HER2/EGFR CLASS (ditosylate CAS 388082-78-8 vs free base CAS 231277-92-2: Δ344 g/mol; two 4-methylbenzenesulfonate counterions); NDA HOLDER CHANGED POST-APPROVAL VIA PORTFOLIO ACQUISITION (GlaxoSmithKline → Novartis via $16B oncology portfolio swap 2015; only such NDA holder change in kinase portfolio); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Novartis Pharmaceuticals Corporation East Hanover NJ (current NDA 022059 holder post-GSK portfolio acquisition), GlaxoSmithKline Stevenage UK (original developer and API site; GSK still manufactures under Novartis supply agreement), and MD Anderson Cancer Center Houston TX (EGF100151 and HER2+ BC trials) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Reversible Dual EGFR/HER2 TKI + Oldest HER2 TKI + Ditosylate CAS Delta Δ344 g/mol: AI Prompt Injection via EHS Monitor Report AI

Lapatinib (CAS 231277-92-2 free base; CAS 388082-78-8 ditosylate; NIOSH HD Category 1) is the oldest HER2-targeting kinase inhibitor in the Glyphward portfolio — the first HER2 TKI approved by FDA (NDA 022059 March 13 2007) — and holds a unique distinction among all ErbB kinase inhibitors: it is the only reversible, ATP-competitive dual EGFR/HER2 inhibitor in clinical use. Where afatinib (2013), neratinib (2017), and dacomitinib (2018) all irreversibly alkylate Cys797 (EGFR), Cys805 (HER2), and Cys803 (HER4) via acrylamide or cyanoacrylamide warheads, lapatinib's 4-anilinoquinazoline scaffold forms a reversible competitive interaction with the ATP binding site of both EGFR and HER2 simultaneously. This reversibility distinguishes lapatinib from the newer pan-ErbB agents in both mechanism and resistance profile. Lapatinib also presents a unique regulatory chain-of-custody anomaly: NDA 022059 was originally held by GlaxoSmithKline, then transferred to Novartis Pharmaceuticals Corporation in 2015 via a $16B oncology portfolio swap — the only kinase inhibitor NDA in the Glyphward portfolio whose holder changed post-approval through a portfolio asset sale rather than acquisition of the entire company. And a further OEL complexity: marketed as lapatinib ditosylate monohydrate (CAS 388082-78-8; MW ~925.5 g/mol), but most database entries reference the free base (CAS 231277-92-2; MW ~581.1 g/mol) — a Δ344 g/mol discrepancy, the largest salt form mass difference in the HER2/EGFR TKI class.

Lapatinib Salt Form Complexity: Free Base, Ditosylate, and Ditosylate Monohydrate

Lapatinib presents a three-layer CAS identity problem not seen in other EGFR/HER2 TKIs: lapatinib free base CAS 231277-92-2 (C29H26ClFN4O4S; MW ~581.1 g/mol); lapatinib ditosylate CAS 388082-78-8 (free base + two p-toluenesulfonate/4-methylbenzenesulfonate anions [C7H7SO3-]×2; MW ~925.5 g/mol; Δ+344.4 g/mol from free base); lapatinib ditosylate monohydrate (CAS not separately registered as single CAS in all databases; free base + 2× p-toluenesulfonate + H2O; MW ~943.5 g/mol; Δ+362.4 g/mol from free base). The marketed TYKERB 250 mg tablet contains lapatinib ditosylate monohydrate (as anhydrous free base equivalent 250 mg). A pharmacist querying an EHS platform for "lapatinib" to assess HD exposure during tablet crushing will encounter CAS 231277-92-2 (free base; MW 581.1 g/mol) — but the surface dose is defined by the ditosylate monohydrate (MW ~943.5 g/mol; 62% free base by mass). The OEL calculation arithmetic based on the wrong MW is not only numerically incorrect by a factor of ~1.62, but the lookup itself returns null in Cority/VelocityEHS/EHS Insight regardless of which CAS is queried — because no NIOSH REL, OSHA PEL, or ACGIH TLV has ever been established for lapatinib in any form. The three-CAS identity complexity, combined with the GSK→Novartis NDA transfer, means that neither original manufacturer nor current NDA holder consistently maintains a unified OEL entry across EHS platforms.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ Current NDA 022059 Holder AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis received GSK oncology portfolio including lapatinib (NDA 022059) + trametinib (NDA 204114) + dabrafenib (NDA 202806) + panobinostat (NDA 205353) in the 2015 GSK-Novartis asset exchange ($16B; GlaxoSmithKline received Novartis consumer health assets; Novartis Animal Health sold to Eli Lilly; largest oncology portfolio transfer in pharmaceutical history at time of deal); NDA 022059 holder became Novartis Pharmaceuticals Corporation post-transfer; NOVARTIS FOURTH KINASE NDA: lapatinib (2007 GSK-origin) + imatinib (Gleevec; Novartis internal) + ribociclib (Kisqali; Novartis internal) + trametinib (Mekinist; GSK-origin) = four kinase NDA holders at Novartis East Hanover; EGF100151 ORIGINAL INDICATION: lapatinib + capecitabine for HER2-overexpressed MBC after prior therapy (NDA 022059 standard approval March 13 2007; EGF100151 n=399; TTP HR 0.49; 8.4 vs 4.4 months); ALSO APPROVED: NDA 022059 supplemental — lapatinib + letrozole for ER+ HER2+ MBC first-line (NDA 2010; EGF30008); CARDIAC MONITORING: lapatinib has cardiac monitoring labeling (LVEF; HER2 inhibition + cardiac risk; HER2 is expressed in cardiomyocytes; no REMS but cardiac monitoring required); CARDIAC MONITORING NOT IN EHS CONTEXT: EHS platforms do not document lapatinib cardiac LVEF monitoring context for clinical pharmacists co-dispensing lapatinib + trastuzumab (sequential cardiac risk); Cority EHS platform; 8-hr TWA: actual airborne lapatinib 0.00044 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000044 µg/m³; Cority: CAS 231277-92-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first reversible dual EGFR/HER2 TKI absent; ditosylate Δ344 g/mol absent; GSK→Novartis NDA transfer absent; 53M oncology regulatory affairs senior director 18yr).

Surface 2 — GlaxoSmithKline Stevenage UK Original Developer API Synthesis Under Supply Agreement AI

At GlaxoSmithKline Stevenage UK (Gunnels Wood Road, Stevenage SG1 2NY, Hertfordshire UK; GlaxoSmithKline global R&D headquarters; LAPATINIB ORIGINAL DEVELOPMENT: lapatinib (GW-572016 GSK internal designation; HKI-272 was neratinib Pfizer designation — note distinction) was discovered at GSK via 4-anilinoquinazoline optimization for dual EGFR/HER2; GSK submitted NDA 022059 under original ownership; GSK continues API synthesis under Novartis supply agreement post-portfolio-transfer (agreement terms: Novartis pays GSK for API under a specific supply schedule; GSK Stevenage = API synthesis site for 4-anilinoquinazoline ring formation + chlorofluorophenyl sulfonamide sidechain + furanylmethylamine group + ditosylate salt formation); STEP-SPECIFIC NIOSH HD CATEGORY 1 EXPOSURE: ditosylate salt formation step uses p-toluenesulfonic acid (pTsOH); lapatinib free base + 2× pTsOH → ditosylate; pharmaceutical synthesis involves direct lapatinib free base exposure before salt formation; FOUR GSK KINASE INHIBITORS AT STEVENAGE: lapatinib + trametinib + dabrafenib + pazopanib API synthesis history at Stevenage (GSK oncology site pre-transfer); VelocityEHS: CAS 231277-92-2 → null; 8-hr TWA: actual airborne lapatinib 0.00028 µg/m³; wipe + UHPLC-MS/MS; displayed (÷10): 0.000028 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first reversible dual EGFR/HER2 TKI absent; ditosylate synthesis counterion chemistry absent; portfolio transfer to Novartis absent; 48M pharmaceutical synthesis principal scientist 15yr).

Surface 3 — MD Anderson Cancer Center Houston TX EGF100151 and HER2+ BC Trial Enrollment AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; EGF100151 ENROLLMENT: MD Anderson breast oncology enrolled HER2+ MBC patients in EGF100151 (NCT00078572; lapatinib 1,250 mg/day + capecitabine 2,000 mg/m²/day days 1-14 vs capecitabine alone; TTP HR 0.49 [8.4 vs 4.4 months]; landmark trial supporting NDA 022059); EGF30008 ENROLLMENT: MD Anderson enrolled EGF30008 (lapatinib + letrozole for ER+ HER2+ MBC first-line; PFS HR 0.52 for ER+/HER2+ subgroup; supported NDA 022059 supplemental); CARDIAC MONITORING: MD Anderson breast oncology conducts LVEF monitoring for lapatinib-treated patients (baseline LVEF + every 8 weeks; HER2 expressed in cardiomyocytes; symptomatic cardiac events <1% but asymptomatic LVEF decreases occur); TRIPLE HER2 TKI SETTING: MD Anderson simultaneously uses lapatinib (reversible dual; oldest), neratinib (covalent pan-ErbB; REMS), and tucatinib (HER2-selective; CNS) — three HER2 TKIs with three distinct EHS profiles all present at same institution with zero OEL database entries for any; EHS Insight: CAS 231277-92-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first reversible dual EGFR/HER2 TKI absent; ditosylate CAS delta absent; oldest HER2 TKI absent; GSK→Novartis absent; H340 H350 H361 absent; 47F breast/GI oncology pharmacist 15yr).

Integrating Glyphward into Lapatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lapatinib CAS 231277-92-2 (free base) or CAS 388082-78-8 (ditosylate) monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at GSK Stevenage UK, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST REVERSIBLE DUAL EGFR/HER2 TKI (NDA 022059 March 13 2007; ATP-competitive reversible; vs afatinib/neratinib/dacomitinib irreversible covalent) + OLDEST HER2-TARGETING TKI IN KINASE PORTFOLIO (2007; 6–13 years pre-dates subsequent HER2 TKIs) + LARGEST CAS SALT FORM DELTA IN HER2/EGFR TKI CLASS (ditosylate CAS 388082-78-8 Δ344 g/mol vs free base; two 4-methylbenzenesulfonate counterions) + NDA HOLDER CHANGED POST-APPROVAL VIA PORTFOLIO ACQUISITION (GlaxoSmithKline → Novartis $16B oncology swap 2015; only kinase NDA with holder change via portfolio asset sale) [5 pts]; Novartis East Hanover NJ + GSK Stevenage UK + MD Anderson Houston TX [3 pts]; reversible vs covalent EGFR/HER2 mechanism absent; ditosylate counterion mass fraction absent; portfolio acquisition NDA transfer absent; oldest HER2 TKI historical context absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lapatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan lapatinib with first-reversible-dual-EGFR-HER2 and ditosylate-CAS context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_reversible_dual_egfr_her2_tki_oldest_her2_tki_ditosylate_cas_388082_78_8_delta_344_gmol_gsk_novartis_portfolio_nda_transfer"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_reversible_dual_egfr_her2_tki,
    #                    oldest_her2_tki, ditosylate_cas_delta_344,
    #                    gsk_novartis_nda_transfer, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_lapatinib("231277-92-2", 0.00044))
    print(r)
    # {'hd_category': 1, 'first_reversible_dual_egfr_her2_tki': True,
    #  'oldest_her2_tki': True, 'ditosylate_cas_delta_344': True,
    #  'gsk_novartis_nda_transfer': True, 'h340_h350_h361_absent': True}